Status
Conditions
Treatments
About
The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19.
The Therma COVID-19 Rapid Antigen Test will be compared to a Health Canada approved RT-PCR COVID-19 test. Nasopharyngeal (for RT-PCR) samples will be collected at a COVID-19 Testing centre and saliva (for the rapid antigen test) samples will be collected and compared.
The prospective, observational, feasibility study will test 300 participants to establish the performance characteristics of the test on saliva specimens.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
300 participants in 1 patient group
Loading...
Central trial contact
Lisa Patterson, BA; Ira Price, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal